Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Non-Coding RNA Assays Market size was over USD 307.83 million in 2024 and is poised to exceed USD 1.76 billion by 2037, growing at over 14.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of non-coding RNA assays is evaluated at USD 382.84 million.
The growth of the market can be attributed to the increasing investment in medical research. Further, the need for assays that can accurately detect and quantify ncRNAs is being driven by the increase in research activities that use these molecules, which is also expected to add to the market growth. As of 2018, total U.S. spending on medical and health research and development (R&D) increased by over 6%.
In addition to these, factors that are believed to fuel the market growth of non-coding RNA assays include the surging government initiatives to promote life science research projects. For instance, in life sciences, research initiatives, non-coding RNA (ncRNA) tests have grown in importance, as they provide information on the roles and control mechanisms of ncRNAs in the cell. Additionally, the growing advancements in technology have enabled the development of more sensitive and accurate ncRNA detection assays, which are predicted to present the potential for market expansion over the projected period.
Non-Coding RNA Assays Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Chronic Diseases – On account of the increasing tobacco use, lack of physical activity, and poor eating habits, the market is expected to expand more in the upcoming years. As per estimates, over 5o% of individuals in the US had at least one chronic disease in 2018.
- Rising Geriatric Population – Elderly population is more prone to chronic illnesses and the increasing number of elderly populations across the globe is estimated to drive market growth. By 2050, the number of Americans aged 65 and older is expected to increase from 48 million to more than 80 million.
- Increasing Drug Discovery – The growing usage of non-coding RNA assays in drug research and development, is estimated to drive market growth. According to the most recent expenditure data, the number of new medications licensed for sale between 2010 and 2019 grew by over 50%.
- Surging Biotechnological Sector – Growing technical developments in industries such as genomics, bioinformatics, and nanotechnology are likely to fuel the market expansion. Further, in initiatives involving genetics and biotechnology, non-coding RNA arrays are employed. By 2025, the Indian biotechnology sector's share of the global biotechnology market is expected to increase by over 15%.
Challenges
- Exorbitant Cost of Non-Coding RNA Assays - The high cost of non-coding RNA assays is one of the major factors predicted to slow down the market growth. For instance, ncRNA assays require specialized equipment such as next-generation sequencing machines, microarray scanners, and qPCR machines, which can be expensive to purchase and maintain.
- Insufficient Researchers in Developing Nations
- The Absence of Standards in ncRNA Analysis
Non-Coding RNA Assays Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
14.4% |
|
Base Year Market Size (2024) |
USD 307.83 million |
|
Forecast Year Market Size (2037) |
USD 1.76 billion |
|
Regional Scope |
|
Non-Coding RNA Assays Segmentation
End-user (Laboratories, Research Centers, Hospitals, Ambulatory Surgical Centers)
The global non-coding RNA assays market is segmented and analyzed for demand and supply by end-user into laboratories, research centers, hospitals, ambulatory surgical centers, and others. Out of the five end-users, the research centers segment is estimated to gain the largest market share in the year 2037. The growth of the segment can be attributed to the increasing prevalence of chronic diseases across the globe. For instance, since ncRNA tests have the potential to serve as biomarkers for illness diagnosis and prognosis, their application in research institutions is becoming more and more crucial. In addition, for a number of illnesses, including cancer, cardiovascular disease, and neurological disorders, ncRNA expression patterns can be employed as biomarkers. Today, an approximate 133 million Americans, or nearly fifty percent of the population, have at least one chronic disease, including hypertension, cardiovascular disease, or arthritis. This figure is 15 substantially larger than a decade ago, and it is projected to surpass 170 million by 2030.
The global non-coding RNA assays market is also segmented and analyzed for demand and supply by end-user into laboratories, research centers, hospitals, ambulatory surgical centers, and others. Amongst these five segments, the laboratories segment is expected to garner a significant share in the year 2036. Using ncRNA assays in laboratory settings is a fast-developing discipline as it offers a potent tool for comprehending how gene expression is regulated and assists in locating possible treatment targets. Besides this, the expression of diverse ncRNA types, including microRNAs, long non-coding RNAs, and small interfering RNAs, in various tissues and cell types may be examined using ncRNA assays in laboratories. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Size |
|
|
By End User |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Non-Coding RNA Assays Industry - Regional Synopsis
North American Market Forecast
North America industry is poised to account for largest revenue share of 40% by 2037. The growth of the market can be attributed majorly to the availability of a large number of biotechnology and pharmaceutical companies. The development and marketing of non-coding RNA tests are made possible by a large number of biotechnology and pharmaceutical firms in the region. For instance, the numerous biotechnology and pharmaceutical firms can contribute to the advancement and commercialization of non-coding RNA tests, resulting in enhanced illness detection and the creation of novel treatment approaches. Further, the increasing government funding for research and development activities is also anticipated to contribute to the market growth in the region. In addition, the region's expanding healthcare industry is also anticipated to boost market growth during the forecast period. As per data, more than 60% of newly approved drugs in the US are the result of work done by small biotech companies.
Europe Market Forecast
The European non-coding RNA assays market is estimated to be the second largest and is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the presence of a large number of academic research institutions. For instance, non-coding RNA assays in the region may be significantly impacted by the presence of academic research institutes. These organizations frequently have access to resources such as skilled researchers, and well-equipped labs that can assist in non-coding RNA research, which as a result is anticipated to contribute to the market growth in the region.
APAC Market Statistics
Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2037. The growth of the market can be attributed majorly to the growing investment in biotech companies. For instance, as the biotechnology industry in the region is growing, it is likely that more companies are assumed to invest in research and development of non-coding RNA assays, which is expected to lead to the development of new technologies and tools for detecting and measuring non-coding RNAs. In addition, this is projected to speed up the search for novel illness biomarkers and the creation of non-coding RNA-targeting medications. Further, the surging development and adoption of advanced biotechnology in developing countries, including, India, China, and Japan, is also anticipated to contribute to the market growth in the region.
Companies Dominating the Non-Coding RNA Assays Landscape
- Thermo Fisher Scientific Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Springer Nature Limited
- Applied Microarrays Inc.
- C D Genomics
- RELX Group
- MilliporeSigma
- QIAGEN
- Agilent Technologies, Inc.
- Danaher Corporation
- Eppendorf SE
Recent Developments
-
QIAGEN introduced QIAseq Targeted DNA Pro Panels and the QIAseq UPXome RNA Library Kit, to speed up the identification of DNA variants and RNA sequencing in low input samples. Further, the new solutions are based on enhanced chemistry that reduces the time required for library construction of DNA samples and establishes new criteria for processing materials in order to identify their nucleic acid sequences.
-
C D Genomics launched Whole Exome Sequencing, to extend its sequencing portfolio. Further, DNA sections known as exomes play a direct role in protein coding, and this approach is mostly employed to discover and investigate mutations in coding and UTR regions.
- Report ID: 3730
- Published Date: Dec 20, 2024
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Non-Coding RNA Assays Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
